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Formulation of a killed whole cell pneumococcus
vaccine - effect of aluminum adjuvants on the
antibody and IL-17 response
Harm HogenEsch1*, Anisa Dunham1, Bethany Hansen1, Kathleen Anderson1, Jean-Francois Maisonneuve2 and
Stanley L Hem3

Abstract
Background: Streptococcus pneumoniae causes widespread morbidity and mortality. Current vaccines contain free
polysaccharides or protein-polysaccharide conjugates, and do not induce protection against serotypes that are not
included in the vaccines. An affordable and broadly protective vaccine is very desirable. The goal of this study was
to determine the optimal formulation of a killed whole cell pneumococcal vaccine with aluminum-containing
adjuvants for intramuscular injection.
Methods: Four aluminium-containing adjuvants were prepared with different levels of surface phosphate groups
resulting in different adsorptive capacities and affinities for the vaccine antigens. Mice were immunized three times
and the antigen-specific antibody titers and IL-17 responses in blood were analyzed.
Results: Although all adjuvants induced significantly higher antibody titers than antigen without adjuvant, the
vaccine containing aluminum phosphate adjuvant (AP) produced the highest antibody response when low doses
of antigen were used. Aluminum hydroxide adjuvant (AH) induced an equal or better antibody response at high
doses compared with AP. Vaccines formulated with AH, but not with AP, induced an IL-17 response. The vaccine
formulated with AH was stable and retained full immunogenicity when stored at 4°C for 4 months.
Conclusions: Antibodies are important for protection against systemic streptococcal disease and IL-17 is critical in
the prevention of nasopharyngeal colonization by S. pneumoniae in the mouse model. The formulation of the
whole killed bacterial cells with AH resulted in a stable vaccine that induced both antibodies and an IL-17
response. These experiments underscore the importance of formulation studies with aluminium containing
adjuvants for the development of stable and effective vaccines.

Background
Streptococcus pneumoniae (pneumococcus) is a Grampositive, encapsulated diplococcus that is commonly
present as a commensal bacterium in the microbial flora
of the upper respiratory tract without causing clinical
disease. However, these bacteria also cause great morbidity and mortality throughout the world. Pneumococcal infections are a leading cause of pneumonia,
bacteremia, meningitis, and otitis media in adults and
children, and account for an estimated 1.6 million
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deaths, including up to 1 million children less than 5
years of age, annually [1-3]. The burden of disease is
greatest in developing countries.
Based on differences in the composition of the polysaccharide capsule, more than 90 distinct serotypes of
pneumococcus are recognized. Current vaccines against
pneumococcus are a 23-valent vaccine containing free
polysaccharides and 7-valent, 10-valent and 13-valent
vaccines composed of protein-polysaccharide conjugates.
The free polysaccharides are T-independent antigens
and induce a poor immune response in children less
than 2 years of age. In contrast, the conjugated vaccines
that are T-dependent induce a good immune response
in young children and infants. These vaccines have

© 2011 HogenEsch et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.

HogenEsch et al. Journal of Immune Based Therapies and Vaccines 2011, 9:5
http://www.jibtherapies.com/content/9/1/5

greatly reduced disease caused by the pneumococcal serotypes included in the vaccines in countries where these
vaccines are widely used. However, the vaccines do not
protect against serotypes that are not included in the
vaccine. Many serotypes in developing countries are not
included in the currently available vaccines and widespread adoption of the vaccines is limited by the cost of
the polysaccharide and conjugate vaccines. Furthermore,
increased prevalence of non-vaccine serotypes has been
observed following the implementation of pneumococcus vaccination programs [4,5]. These considerations
have led to the pursuit of alternative vaccination strategies, including the use of protein antigens that are
shared among the different serotypes. A potentially successful approach is the use of killed, non-encapsulated
pneumococci (whole cell antigen - WCA) which provides multiple common antigens for inducing an
immune response that is protective across the different
serotypes, and is relatively inexpensive to prepare [6].
Previous studies showed that intranasal immunization
with WCA and cholera toxin as a mucosal adjuvant,
induced a robust antibody response [7]. The inoculated
mice had greatly reduced nasopharyngeal and middle
ear colonization following intranasal administration of
pneumococci of different serotypes [7-9]. Similarly
inoculated rats were protected from sepsis against
intrathoracic challenge with serotype 3 [7]. The protection against nasopharyngeal colonization in mice
occurred in antibody-deficient mice, and was dependent
on the presence of CD4 + T cells. Subsequent studies
demonstrated that this protection was conferred by
Th17 cells, whereas IL-4 and IFN-g were not necessary
for protection [10].
Although mucosal administration of vaccines has several advantages, the need for cholera toxin to induce an
effective immune response precludes this route of immunization for human use until acceptable mucosal adjuvants become available. Vaccines for intramuscular
injection often contain aluminum compounds as safe,
effective, and inexpensive adjuvants. The two aluminumcontaining adjuvants that are commercially available and
widely used in vaccines are aluminum hydroxide (AH)
and aluminum phosphate (AP) [11]. These adjuvants
have large adsorptive surfaces, but different structural
and surface properties which affect their interaction with
vaccine antigens. Adsorption of antigens onto aluminum
adjuvants increases the retention of antigens at the injection site and this property was considered essential for
the immunostimulatory effect ("depot-mechanism”).
However, recent studies indicate that adsorption is not
necessary for the adjuvant effect of aluminum compounds [12-14]. Nevertheless, adsorption may affect the
structural stability of antigens and the availability of epitopes [15,16]. The two main mechanisms by which
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antigens adsorb onto aluminum-containing adjuvants are
electrostatic attraction and ligand exchange [11]. The
surface charge of AH is positive at neutral pH and that of
AP is negative at neutral pH. Therefore, these adjuvants
have different affinities for antigens that adsorb through
electrostatic mechanisms. Electrostatically adsorbed antigens usually elute from the adjuvants upon exposure to
interstitial fluid following intramuscular or subcutaneous
administration [17]. Ligand exchange is the replacement
of surface hydroxyls by terminal phosphate groups of
phosphorylated antigens creating a covalent bond that is
stronger than electrostatic adsorption. Since AH has
more surface hydroxyls than AP, it has a higher affinity
for phosphorylated antigens. Such strong adsorption
results in poor elution in interstitial fluid and has a negative effect on the immune response to phosphorylated
antigens formulated with AH as opposed to AP [18].
Our previous work with aluminium-containing adjuvants was based on single antigens. Here, we report on
experiments aimed at formulating WCA, a complex
mixture of antigens, with aluminum adjuvants. The goal
was to determine the formulation that induced the maximum antibody and IL-17 response, two critical components of a protective immune response against S.
pneumoniae [6]. These studies for the first time demonstrate that the type of aluminum-containing adjuvants
(AH vs. AP) affects the magnitude and quality of the
antibody response as well as the Th17 CD4 + T cell
response to WCA.

Methods
Mice

All experiments involving mice were conducted in accordance with NIH guidelines for the care and use of experimental animals and were approved by the Purdue
University Animal Care and Use Committee. Seven week
old female C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Mice were maintained
in a conventional barrier facility, exposed to a 12 h light/
12 h dark cycle, and allowed free access to water and
LabDiet 5015 (Purina Mills, Richmond, IN, USA). They
were acclimated for one week, and injected with 50 μl of
vaccine intramuscularly in each hind leg (100 μL/mouse)
two or three times with a two-week interval. Immediately
prior to the last injection, blood was collected from the
facial vein. Two weeks after the last injection, mice were
anesthetized, blood was collected in heparinized tubes,
and the mice were euthanized. Serum and plasma were
separated by centrifugation at 14,000 × g for 10 min and
stored at -80°C until analysis.
Vaccine preparations

The whole cell bacterial antigen (WCA) consists of a
suspension of strain Rx1E, a capsule-deficient, autolysin-

HogenEsch et al. Journal of Immune Based Therapies and Vaccines 2011, 9:5
http://www.jibtherapies.com/content/9/1/5

negative mutant of Streptococcus pneumoniae, killed by
treatment with beta-propiolactone [19]. The stock solution (prepared by Instituto Butantan, Sao Paulo, Brazil)
contained 1010 cells/mL (corresponding with 10 mg protein/mL) in Ringer’s solution.
Vaccines were prepared with 4 different adjuvants.
Aluminum hydroxide adjuvant (Alhydrogel “85” 2%) and
AP (AdjuPhos) were obtained from Brenntag Biosector
(Denmark). Phosphate-treated AH (PTAH) and phosphate treated AP (PTAP) were prepared by mixing the
adjuvants with 60 mM phosphate buffer for 16 hours at
room temperature.
Vaccines were prepared aseptically by adding different
amounts of WCA as indicated in the text to adjuvants
at 1.2 mg Al/mL and mixing for 1 h at room
temperature.
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Rockford, IL) and incubated for 10 minutes at 70°C.
The proteins were separated on a 4-12% gradient gel
(Invitrogen) and transferred onto nitrocellulose. Individual strips were blocked with non-fat milk, incubated
with pooled plasma at 1:500 dilution from each of the
experimental groups, and then with peroxidase-labeled
goat anti-mouse IgG. Bands were visualized with an
ECL detection kit.
IL-17 assay

Forty microliters of heparinized blood was added to 360
μL of Iscove’s Modified Eagle Medium supplemented
with 10% fetal calf serum, 10 μg/mL ciprofloxacin, and
107 WCA/mL. After incubation for 6 days at 37°C and
5% CO2, supernatants were collected and stored at -80°
C until analysis by ELISA for IL-17A (IL17; R&D Systems, Minneapolis, MN).

Adsorption isotherms

Vaccines were prepared as described above with different WCA concentrations. After incubation for 1 h at 4°
C, the suspension was layered over a 60% sucrose gradient and centrifuged for 20 minutes at 1,500 × g to separate non-adsorbed WCA from adsorbed WCA. The
supernatant was collected and protein content was
determined by bicinchoninic acid protein assay (Pierce,
Rockford, IL) in triplicate. The adsorption data was
plotted according to the linear form of the Langmuir
equation. The adsorptive coefficient was calculated as
the slope/intercept and the adsorptive capacity was calculated as the reciprocal of the slope.

Statistical analysis

The anti-WCA IgG concentrations were log2 transformed prior to analysis by one-way ANOVA followed
by a Newman-Keuls multiple comparison test (Graphpad Prism, version 5.02). Differences between groups at
p < 0.05 were considered significant. The statistical significance of differences between means of IL-17 among
experimental groups was determined by two-way
ANOVA followed by Bonferroni post-hoc test with p <
0.05.

Results
Adsorption of WCA onto aluminum-containing adjuvants

Light microscopy of vaccine preparations

The bacterial cells in WCA were stained with gentian
violet prior to mixing with AH and AP. The stained
cells were mixed with each adjuvant and examined by
light microscopy using a 100× oil immersion objective.
Anti-WCA ELISA

Ninety-six well plates were coated with WCA (108/mL)
overnight, blocked with 5% fetal calf serum diluted in
PBS, and incubated with serially diluted standard and
serum or plasma samples starting at a 1:100 dilution.
The plates were then incubated with peroxidase-labeled
goat anti-mouse IgG (Sigma, St. Louis, MO), followed
by 3,3’,5,5’ - tetramethylbenzidine substrate. After addition of a 2 N sulfuric acid stop solution the color intensity was measured in a microplate reader (Biotek,
Winooski, VT) at 450 nm. A standard curve was constructed using serum with high antibody titer, arbitrarily
set at 120,000 U/mL.

Four different adjuvants were prepared and incubated
with different doses of WCA to determine the adsorptive capacity and coefficient. The adsorptive capacity
and adsorptive coefficient (adsorptive strength) of AH
was greatest, followed by AP and then PTAH (Table 1).
There was no detectable adsorption of protein to PTAP.
The adsorption of the bacterial cells to each adjuvant
was verified by light microscopy using gentian violetstained bacteria (Figure 1). The bacteria were associated
with the AH and AP aggregates and were not observed
in the liquid phase separating the adjuvant aggregates.

Table 1 Adsorptive capacity and adsorptive coefficient
(affinity) of the different adjuvants for WCA calculated
from Langmuir adsorption isotherms.

Immunoblot of plasma samples

The WCA was diluted to 109/mL in lithium dodecyl sulfate (LDS) sample buffer (Thermo Fisher Scientific,

a

Langmuir isotherm
coefficient

WCA/
AH

WCA/
AP

WCA/
PTAH

WCA/
PTAP

Adsorptive capacity
(mg/mg Al)

0.22

0.07

0.03

-

a

Adsorptive coefficient
(mL/mg)

4500

2026

803

-

a

Adsorptive capacity and coefficient could not be determined because there
was no detectable adsorption.
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Figure 1 Phosphate treatment of aluminum hydroxide adjuvant and aluminum phosphate adjuvant prevented the adsorption of
bacterial pneumococcal cells. Light microscopy of WCA mixed with the aluminum-containing adjuvants, aluminum hydroxide adjuvant (AH),
aluminum phosphate adjuvant (AP), phosphate-treated AH (PTAH) and phosphate-treated AP (PTAP). The bacteria were stained with gentian
violet, and the suspensions were examined using a 100× oil objective.

In the case of PTAH and PTAP, the bacteria were largely present in the liquid regions. These bacteria were
moving freely by Brownian motion while the cells associated with the AH and AP adjuvant aggregates were
stationary. Thus, the observations by light microscopy
concurred with the data derived from the adsorption
isotherms (Table 1).
Antibody response to vaccines formulated with four
different adjuvants

Mice were injected with WCA (107 cells) alone or combined with one of the four adjuvants. After two injections, blood was collected and the concentration of antiWCA IgG was determined. All four adjuvants enhanced
the antibody response over WCA alone. The highest
concentration of anti-WCA IgG was observed in mice
injected with WCA/AP, followed by WCA/PTAP,
WCA/PTAH, and WCA/AH (Figure 2). The difference
between WCA/AP and WCA/AH was statistically
significant.
Effect of AH vs. AP on antibody and IL-17 responses

Since phosphate treatment of the AH and AP adjuvants
did not enhance the immunostimulatory effect of these
adjuvants, subsequent experiments were conducted with

AH and AP only. Mice were injected with 3 different
doses of WCA alone or combined with AH or AP.
Blood was collected after two and three injections for
the determination of anti-WCA antibody concentrations,
and after three injections for IL-17 production. The
adjuvants significantly enhanced the antibody response
to WCA at all three doses and after two as well as three
immunizations (Figure 3). The anti-WCA IgG concentration generally increased with increasing dose and
after more immunizations. At the lowest dose of WCA
(106 cells), the mice that received WCA/AP generated a
stronger antibody response than mice injected with
WCA/AH. At the intermediate dose (107 cells), WCA/
AP induced a stronger antibody response after two
injections, while there was no difference between the
WCA/AP and WCA/AH groups after three injections.
There was also no difference between WCA/AP and
WCA/AH after two injections of the highest dose (108
cells), but after three injections the mice that received
WCA/AH had the highest IgG concentration. Previous
experiments showed that anti-WCA IgG concentrations
> 10,000 units/mL are protective upon challenge in
mice [19]. These values were consistently obtained after
three injections with 107 and 108 cells when formulated
with AP, and with 108 cells when formulated with AH.
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combination with AH. There was no detectable IL-17 in
blood cultures from any of the other groups (Figure 5).
Stability of the WCA/AH vaccine formulation

Figure 2 IgG titers in mice injected with vaccines with different
types of aluminium-containing adjuvants. Mice (n = 8/group)
were injected twice with WCA (107 cells/dose) alone or combined
with four different aluminum-containing adjuvants. The IgG titer in
serum was determined two weeks after the second injection. The
symbols represent individual mice and the horizontal line indicates
the geometric mean. The geometric means of groups with different
letters are different at p < 0.05.

Thus, the effect of aluminum-containing adjuvants is
dose-dependent with AP generating a stronger antibody
response at lower antigen doses.
The adjuvants AH and AP have opposite surface
charges at pH 6-7 resulting in different affinities for proteins with different isoelectric points. To determine if
these differences affect which WCA proteins induce an
antibody response, an immunoblot was performed with
WCA as substrate and pooled plasma from mice in each
of the vaccine groups (Figure 4). The antibodies reacted
with a range of proteins varying in size from less than
20 kD to over 200 kD. Consistent with the ELISA
results, the bands from mice immunized with the highest dose of WCA in combination with AH had the
greatest intensity. Antibodies from mice injected with
adjuvanted WCA reacted with more proteins than antibodies from mice injected with WCA only. In addition,
there were several proteins in the 30 - 60 kD range that
reacted only with antibodies from mice immunized with
AH or with AP-adjuvanted vaccines (Figure 4).
The concentration of IL-17A (IL-17) was determined
in the supernatant of whole blood cultures following
incubation with WCA for 6 days. A significant concentration of IL-17 was only detected in cultures from mice
injected with the intermediate and high dose of WCA in

To determine the effect of prolonged storage of the
WCA/AH vaccine on the immune response, the high
dose of WCA (10 8 cells/dose) was prepared with or
without AH and stored for 4 months at 4°C. Mice were
injected 3 times with stored and freshly prepared vaccines and the immune response was analyzed as
described above. A greater IgG response was observed
after three compared with two injections. The IgG
response obtained with the stored vaccine formulation
was slightly lower than that obtained with the freshly
prepared formulation (geometric mean of freshly prepared WCA was 9,073 vs. 6,754 for stored WCA; geometric mean of freshly prepared WCA/AH was 60,256
vs. 41,688 for stored WCA/AH), but the difference was
not statistically significant (Figure 6A). Importantly, the
IgG titers in mice immunized with the stored vaccine
were well above the minimum protective level of 10,000
units/mL. There was no difference in the concentration
of IL-17 in supernatants of whole blood cultures of
mice immunized with WCA/AH (Figure 6B).

Discussion
Vaccines against pneumococcal disease for use in developing countries should be safe, effective against a broad
range of serotypes and affordable. The existing conjugate vaccines offer protection against the serotypes
included in the vaccine which were selected based on
their prevalence in North America and Europe, and are
predicted to provide incomplete protection against
pneumococcal infections in Asia and Africa. In addition,
these conjugate vaccines are expensive to produce. The
work in this report demonstrates that a vaccine composed of killed whole cell, nonencapsulated pneumococci and formulated with AH, induces a strong
antibody and IL-17 response. Both the antigen and adjuvant are relatively inexpensive suggesting that the vaccine will be affordable for use in developing countries.
Previous work with a simple protein antigen, alpha
casein, indicated that the strength of adsorption of antigens onto aluminum-containing adjuvants is inversely
related to the antibody response to these antigens [18].
A similar relationship was found with a larger and more
complex antigen, hepatitis B surface antigen (HBsAg),
but the negative effect of a high adsorptive coefficient
was not as strong as with alpha casein [20]. The antigen
used in the current studies, WCA, consists of killed
whole bacterial cells and some soluble bacterial proteins.
WCA was mixed with four aluminum-containing adjuvants with different surface properties to determine if
differences in adsorptive capacity and adsorptive
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Figure 3 IgG titers in mice injected with vaccines formulated with AH and AP and different doses of WCA. Mice were immunized twice
with WCA at 106 cells (A), 107 cells (B) and 108 cells (C) per dose, or three times with WCA at 106 cells (D), 107 cells (E) and 108 cells (F) per
dose. The symbols represent individual mice (n = 4/group for WCA alone and n = 8 for WCA/AH and WCA/AP) and the horizontal line indicates
the geometric mean.
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Figure 4 Antigen specificity of IgG from mice injected with
vaccines formulated with AH and AP. Immunoblot of WCA with
antibodies in pooled plasma from mice injected three times with
WCA only at 108/dose (lane 1); WCA/AP at 108/dose (lane 2), 107/
dose (lane 3), 106/dose (lane 4); and WCA/AH at 108/dose (lane 5),
107/dose (lane 6), 106/dose (lane 7). Plasma was collected 2 weeks
after the last injection.

coefficient could be measured. Although the obtained
values should be interpreted with caution because of the
complex nature of WCA, they indicate a range of
adsorptive properties for the four adjuvants. The highest
values were measured for AH while adjuvants with

Figure 5 Vaccines of WCA formulated with AH, but not with
AP or vaccines without adjuvants induced an IL-17 response.
IL-17 concentration in the supernatant of whole blood cultures
incubated for 6 days with WCA (107/mL). The blood was collected
from mice injected three times with WCA, WCA/AH or WCA/AP at
106 cells/dose, 107 cells/dose or 108 cells/dose. The bars indicate the
mean ± SEM of 8 mice per group. * p < 0.05; ** p < 0.005 (WCA/
AH vs. WCA and WCA/AH vs. WCA/AP).
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more surface phosphates had a lower affinity for WCA.
This suggests that at least some of the molecules in
WCA are phosphorylated or associated with phospholipid membranes, and are adsorbed by the ligand
exchange mechanism.
The antibody response to the vaccine formulations
with the four adjuvants with broadly divergent adsorptive capacities and coefficients for WCA indicated that
the aluminum-containing adjuvant potentiated the
immune response even when the antigen was not
adsorbed. In addition, the strength of adsorption was
not a significant factor in immunopotentation. Aluminum adjuvants may enhance the immune response to
soluble antigens by adsorbing the antigens onto the
adjuvant particles that are more readily phagocytised by
antigen-presenting cells [21]. Antigen adsorption by the
adjuvant may be less relevant when the antigen comprises killed whole cell bacteria as the bacteria are about
1 micrometer in diameter while the primary particles of
the adjuvant are smaller than 50 nm [11]. Since changes
in adsorption through phosphate treatment of the adjuvants did not affect the antibody response, subsequent
experiments focused on AH and AP.
The protective immune response induced by conjugate
vaccines is based on serotype-specific anti-polysaccharide antibodies. In contrast, the immune response against
WCA involves antibodies directed against protein antigens and Th17 cells. Antibodies induced by WCA can
provide protection against systemic disease, but they do
not protect against nasopharyngeal colonization in mice
[7,9]. Nasopharyngeal colonization was inhibited by CD4
+
T cells that secrete IL-17, and the concentration of IL17 in WCA-stimulated whole blood cultures was inversely correlated with the degree of nasopharyngeal colonization following intranasal challenge [10]. Infection of
naïve mice with S. pneumonia induced Th17 cells which
provided enhanced clearance of the bacteria upon secondary challenge [22]. The protective role of IL-17
resides in the induction of secretion of antimicrobial
peptides and chemokines that attract monocytes and
neutrophils to the site of infection [23,24]. IL-17 is also
involved in the protection against other extracellular
bacterial pathogens such as Bordetella pertussis, intracellular bacterial pathogens including Mycobacterium
tuberculosis, and fungal pathogens, indicating an important role against infections at mucosal surfaces and in
the lung. However, an excessive IL-17 response may be
detrimental and cause extensive tissue damage [23,24].
It has been suggested that Th17 cells are critical for vaccine-induced memory immune responses, and enhancing and regulating the Th17 response may be
important in vaccine design [24]. In our studies, the
combination of WCA with AH was critical for the
induction of a population IL-17 producing cells
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Figure 6 Immunogenicity of the WCA/AH vaccine formulation stored for 4 months at 4°C. Mice were immunized three times with WCA
(108 cells/dose) and WCA/AH stored at 4°C for four months (s) or with freshly prepared WCA and WCA/AH (f). The IgG titer was determined in
plasma collected 2 weeks after the last injection. The IL-17 concentration was determined in the supernatant of whole blood cultures stimulated
with WCA.

following intramuscular injection. Neither WCA alone
nor WCA with AP induced a significant IL-17 response,
even though AP greatly enhanced the antibody response
to WCA. Such a dramatic difference in the quality of
the immune response between vaccines formulated with
AH and vaccines formulated with AP was unexpected.
The induction of Th17 cells in S. pneumoniae infection is dependent on TLR2 [22]. The ligands for TLR2
include molecular components of Gram-positive bacteria
such as lipoproteins [25,26]. The induction of Th17 cells
by WCA/AH and not by WCA/AP suggests that these
ligands are not available in the WCA/AP formulation,
possibly due to strong electrostatic adsorption.
There are few published reports in which the
immune responses to bacterial vaccines formulated
with AP vs. AH are directly compared. In one study,
acellular pertussis antigens combined with AH induced
a stronger antibody response and greater protection
upon intranasal challenge with Bordetella pertussis
compared with AP, but the basis of the increased protection was not further investigated [27]. Th17 cells
are induced during infection with Bordetella pertussis,
but antibody-mediated depletion of IL-17 only had a
modest effect on the bacterial loads in the lungs of
experimentally infected mice [28]. Two types of vaccines, a whole cell and an acellular pertusiss vaccine,
are used to protect against whooping cough. Both vaccines are effective, but vaccination of mice with a
whole cell pertussis vaccine induced Th17 cells,
whereas these cells were not induced by the acellular

vaccine [29,30]. The role of adjuvants was not specifically addressed in these studies.
The basis for the difference in immune response generated by WCA formulated with AH vs. AP is not
entirely clear, but it is likely that the greater affinity of
AH for WCA proteins contributed to this effect. The
adsorptive strength, determined as the adsorptive coefficient, of AH was 2.5 times that of AP. Previous work
showed that a high adsorptive strength may interfere
with the antibody response and the T cell response,
probably because there is insufficient release of antigen
from the adjuvant to interact with B cells and for antigen processing and presentation [18]. A similar effect
was observed at the lower doses of WCA in which a significantly stronger antibody response was obtained with
AP in comparison with AH. At higher doses, the difference between AP and AH disappeared and AH induced
a stronger antibody response than AP at the highest
antigen dose.
Immunoblot analysis revealed qualitative and quantitative differences in the antigenic proteins recognized by
antibodies from the mice injected with different WCA
formulations. The antibodies from mice injected with
adjuvanted WCA reacted with more proteins than those
from mice injected with non-adjuvanted WCA. Antibodies from mice injected with WCA/AH and WCA/AP
reacted with an overlapping, but different set of proteins. The surface of AH and AP have opposite charges
at pH 6-7 resulting in different affinities for individual
proteins within the WCA. This may in turn affect which

HogenEsch et al. Journal of Immune Based Therapies and Vaccines 2011, 9:5
http://www.jibtherapies.com/content/9/1/5

antigens from this complex protein mixture induce antibodies. Further studies are necessary to determine the
biological significance of these differences in antibody
specificities.
Long term stability of vaccines is an important consideration. In order to assess the stability of the WCA/AH
vaccine formulation, the effect of prolonged storage at
4°C on the immune response was determined. There
was no significant difference between the stored and
freshly prepared formulations indicating that the WCA/
AH is quite stable.

Conclusions
The goal of these experiments was to determine the
optimal formulation of a killed pneumococcal vaccine
with aluminium-containing adjuvants. The data indicate
that formulation of WCA with AH induces a strong
antibody and Th17 response, and AH is the preferred
choice over AP for vaccines for intramuscular administration. The marked differences in the antibody and cellular response to the two aluminum-containing
adjuvants underscores the importance of proper pre-formulation studies in preparing safe and effective vaccines
[31,32].
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